Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/prognostic-factors-for-chronic-lymphocytic-leukemia-Meqg5FJJHC
References (45)
-
O. Monni, S. Knuutila (2001)
11q Deletions in Hematological MalignanciesLeukemia & Lymphoma, 40
-
S. Böttcher, M. Ritgen, K. Fischer, S. Stilgenbauer, R. Busch, G. Fingerle-Rowson, A. Fink, A. Bühler, T. Zenz, M. Wenger, M. Mendila, C. Wendtner, B. Eichhorst, H. Döhner, M. Hallek, M. Kneba (2012)
Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 9
-
N. Pflug, J. Bahlo, T. Shanafelt, B. Eichhorst, M. Bergmann, T. Elter, Kathrin Bauer, G. Malchau, K. Rabe, S. Stilgenbauer, H. Döhner, U. Jäger, M. Eckart, G. Hopfinger, R. Busch, A. Fink, C. Wendtner, K. Fischer, N. Kay, M. Hallek (2014)
Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia.Blood, 124 1
-
Jennifer Brown, J. Barrientos, P. Barr, I. Flinn, J. Burger, A. Tran, F. Clow, D. James, T. Graef, J. Friedberg, K. Rai, S. O'brien (2015)
The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia.Blood, 125 19
-
P. Thompson, S. O'brien, W. Wierda, A. Ferrajoli, F. Stingo, Susan Smith, J. Burger, Z. Estrov, N. Jain, H. Kantarjian, M. Keating (2015)
Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib‐based regimensCancer, 121
-
R. Claus, D. Lucas, A. Ruppert, K. Williams, D. Weng, Kara Patterson, M. Zucknick, C. Oakes, L. Rassenti, Andrew Greaves, S. Geyer, W. Wierda, Jennifer Brown, J. Gribben, J. Barrientos, K. Rai, N. Kay, T. Kipps, P. Shields, Weiqiang Zhao, M. Grever, C. Plass, J. Byrd (2014)
Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia.Blood, 124 1
-
A. Hurtado, T. Chen-Liang, B. Przychodzen, C. Hamedi, J. Muñoz-Ballester, B. Dienes, M. García-Malo, A. Antón, F. Arriba, R. Teruel-Montoya, F. Ortuño, V. Vicente, J. Maciejewski, A. Jerez (2015)
Prognostic signature and clonality pattern of recurrently mutated genes in inactive chronic lymphocytic leukemiaBlood Cancer Journal, 5
-
D. Rossi, M. Cerri, C. Deambrogi, E. Sozzi, S. Cresta, S. Rasi, L. Paoli, V. Spina, V. Gattei, D. Capello, F. Forconi, F. Lauria, G. Gaidano (2009)
The Prognostic Value of TP53 Mutations in Chronic Lymphocytic Leukemia Is Independent of Del17p13: Implications for Overall Survival and ChemorefractorinessClinical Cancer Research, 15
-
L. Rassenti, Sonia Jain, M. Keating, W. Wierda, M. Grever, J. Byrd, N. Kay, Jennifer Brown, J. Gribben, D. Neuberg, F. He, Andrew Greaves, K. Rai, T. Kipps (2008)
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia.Blood, 112 5
-
Greg Matlashewski, Peter Lamb, D. Pim, Jim Peacock, Lionel Crawford, Sam Benchimoll (1984)
Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene.The EMBO Journal, 3
-
D. Rossi, S. Rasi, V. Spina, A. Bruscaggin, S. Monti, C. Ciardullo, C. Deambrogi, Hossein Khiabanian, R. Serra, F. Bertoni, F. Forconi, L. Laurenti, R. Marasca, M. Dal-Bo, F. Rossi, P. Bulian, J. Nomdedéu, G. Poeta, V. Gattei, L. Pasqualucci, R. Rabadán, R. Foà, R. Dalla-Favera, G. Gaidano (2013)
Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia.Blood, 121 8
-
A. Roberts, Shuo Ma, D. Brander, T. Kipps, J. Barrientos, M. Davids, M. Anderson, C. Tam, Tanita Mason-Bright, Nikita Rudersdorf, Lori Gressick, Jianning Yang, W. Munasinghe, Ming Zhu, E. Cerri, S. Enschede, R. Humerickhouse, J. Seymour (2014)
Determination of Recommended Phase 2 Dose of ABT-199 (GDC-0199) Combined with Rituximab (R) in Patients with Relapsed / Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)Blood, 124
-
Sara Raponi, I. Starza, M. Propris, I. Giudice, F. Mauro, M. Marinelli, V. Maio, A. Piciocchi, R. Foà, A. Guarini (2014)
Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ‐PCRBritish Journal of Haematology, 166
-
H. Döhner, S. Stilgenbauer, A. Benner, E. Leupolt, A. Kröber, L. Bullinger, K. Döhner, Martin Bentz, P. Lichter (2000)
Genomic aberrations and survival in chronic lymphocytic leukemia.The New England journal of medicine, 343 26
-
T. Hamblin, Z. Davis, A. Gardiner, D. Oscier, F. Stevenson (1999)
Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.Blood, 94 6
-
J. Byrd, R. Furman, S. Coutre, J. Burger, K. Blum, M. Coleman, W. Wierda, Jeffrey Jones, Weiqiang Zhao, N. Heerema, A. Johnson, Yun Shaw, Elizabeth Bilotti, Cathy Zhou, D. James, S. O'brien (2015)
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.Blood, 125 16
-
N. Jain, S. O'brien (2015)
Initial treatment of CLL: integrating biology and functional status.Blood, 126 4
-
J. Lee, D. Dixon, H. Kantarjian, M. Keating, M. Talpaz (1987)
Prognosis of chronic lymphocytic leukemia: a multivariate regression analysis of 325 untreated patients.Blood, 69 3
-
J. Riches, Conor O’Donovan, S. Kingdon, F. McClanahan, A. Clear, D. Neuberg, L. Werner, C. Croce, A. Ramsay, L. Rassenti, T. Kipps, J. Gribben (2014)
Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations.Blood, 123 26
-
H. Döhner, S. Stilgenbauer, M. James, A. Benner, Traudel Weilguni, Martin Bentz, K. Fischer, W. Hunstein, P. Lichter (1997)
11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis.Blood, 89 7
-
P. Bulian, T. Shanafelt, C. Fegan, A. Zucchetto, L. Cro, H. Nückel, L. Baldini, A. Kurtova, A. Ferrajoli, J. Burger, G. Gaidano, G. Poeta, C. Pepper, D. Rossi, V. Gattei (2013)
CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 9
-
T. Shanafelt, S. Geyer, N. Bone, R. Tschumper, T. Witzig, G. Nowakowski, C. Zent, T. Call, B. Laplant, G. Dewald, D. Jelinek, N. Kay (2008)
CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potentialBritish Journal of Haematology, 140
-
M. Hallek, I. Langenmayer, C. Nerl, W. Knauf, H. Dietzfelbinger, D. Adorf, Marianne Ostwald, R. Busch, I. Kuhn-Hallek, E. Thiel, B. Emmerich (1999)
Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia.Blood, 93 5
-
K. Rai, A. Sawitsky, E. Cronkite, A. Chanana, R. Levy, B. Pasternack (1975)
Clinical staging of chronic lymphocytic leukemia.Blood, 46 2
-
D. Gladstone, L. Swinnen, Y. Kasamon, A. Blackford, C. Gocke, C. Griffin, J. Meade, Richard Jones (2011)
Importance of immunoglobulin heavy chain variable region mutational status in del(13q) chronic lymphocytic leukemiaLeukemia & Lymphoma, 52
-
S. Konoplev, H. Fritsche, S. O'brien, W. Wierda, M. Keating, T. Gornet, Susan Romain, Xuemei Wang, K. Inamdar, Malisha Johnson, L. Medeiros, C. Bueso-Ramos (2010)
High serum thymidine kinase 1 level predicts poorer survival in patients with chronic lymphocytic leukemia.American journal of clinical pathology, 134 3
-
K. Maddocks, A. Ruppert, G. Lozanski, N. Heerema, Weiqiang Zhao, L. Abruzzo, A. Lozanski, Melanie Davis, Amber Gordon, Lisa Smith, Rose Mantel, Jeffrey Jones, J. Flynn, S. Jaglowski, L. Andritsos, F. Awan, K. Blum, M. Grever, A. Johnson, J. Byrd, J. Woyach (2015)
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.JAMA oncology, 1 1
-
M. Oken, R. Creech, D. Tormey, J. Horton, T. Davis, E. McFadden, P. Carbone (1982)
Toxicity and response criteria of the Eastern Cooperative Oncology GroupAMERICAN JOURNAL OF CLINICAL ONCOLOGY, 5
-
J. Dürig, M. Naschar, U. Schmücker, K. Renzing-Köhler, Tanja Hölter, A. Hüttmann, Ulrich Dührsen (2002)
CD38 expression is an important prognostic marker in chronic lymphocytic leukaemiaLeukemia, 16
-
M. Isobe, B. Emanuel, D. Givol, M. Oren, C. Croce (1986)
Localization of gene for human p53 tumour antigen to band 17p13Nature, 320
-
Binet Jl, A. Auquier, G. Dighiero, C. Chastang, H. Piguet, J. Goasguen, G. Vaugier, G. Potron, P. Colona, F. Oberling, Mark Thomas, G. Tchernia, C. Jacquillat, P. Boivin, C. Lesty, M. Duault, M. Monconduit, S. Belabbes, F. Grémy (1981)
A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysisCancer, 48
-
F. Gumy-Pause, P. Wacker, A. Sappino (2004)
ATM gene and lymphoid malignanciesLeukemia, 18
-
Gabriele Brachtl, J. Hofbauer, R. Greil, T. Hartmann (2013)
The pathogenic relevance of the prognostic markers CD38 and CD49d in chronic lymphocytic leukemiaAnnals of Hematology, 93
-
M. Bo, E. Tissino, D. Benedetti, Chiara Caldana, R. Bomben, G. Poeta, G. Gaidano, F. Rossi, A. Zucchetto, V. Gattei (2014)
Microenvironmental interactions in chronic lymphocytic leukemia: the master role of CD49d.Seminars in hematology, 51 3
-
J. Byrd, R. Furman, S. Coutre, I. Flinn, J. Burger, K. Blum, B. Grant, J. Sharman, M. Coleman, W. Wierda, Jeffrey Jones, Weiqiang Zhao, N. Heerema, A. Johnson, J. Sukbuntherng, B. Chang, F. Clow, E. Hedrick, J. Buggy, D. James, S. O'brien (2013)
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.The New England journal of medicine, 369 1
-
A. Visentin, M. Facco, F. Frezzato, M. Castelli, V. Trimarco, V. Martini, Cristina Gattazzo, Filippo Severin, G. Chiodin, A. Martines, L. Bonaldi, Ilaria Gianesello, E. Pagnin, E. Boscaro, F. Piazza, R. Zambello, G. Semenzato, L. Trentin (2015)
Integrated CLL Scoring System, a New and Simple Index to Predict Time to Treatment and Overall Survival in Patients With Chronic Lymphocytic Leukemia.Clinical lymphoma, myeloma & leukemia, 15 10
-
M. Gentile, F. Mauro, D. Rossi, I. Vincelli, G. Tripepi, A. Recchia, Laura Stefano, M. Campanelli, D. Giannarelli, S. Bossio, L. Morabito, E. Vigna, G. Gaidano, R. Foà, F. Morabito (2014)
Italian external and multicentric validation of the MD Anderson Cancer Center nomogram and prognostic index for chronic lymphocytic leukaemia patients: analysis of 1502 casesBritish Journal of Haematology, 167
-
C. Tam, S. O'brien, W. Wierda, H. Kantarjian, S. Wen, K. Do, D. Thomas, J. Cortes, S. Lerner, M. Keating (2008)
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.Blood, 112 4
-
A. Majid, T. Lin, Giles Best, K. Fishlock, S. Hewamana, G. Pratt, D. Yallop, A. Buggins, S. Wagner, B. Kennedy, F. Miall, R. Hills, S. Devereux, D. Oscier, M. Dyer, C. Fegan, C. Pepper (2011)
CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL.Leukemia research, 35 6
-
O. McBride, D. Merry, D. Givol (1986)
The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13).Proceedings of the National Academy of Sciences of the United States of America, 83 1
-
Veronica Balatti, Yuri Pekarky, C. Croce (2015)
Role of microRNA in chronic lymphocytic leukemia onset and progressionJournal of Hematology & Oncology, 8
-
M. Weisser, R. Yeh, G. Duchateau-Nguyen, G. Palermo, T. Nguyen, Xiaoyan Shi, Susanna Stinson, N. Yu, A. Dufour, T. Robak, G. Salogub, A. Dmoszyńska, P. Solal-Céligny, K. Warzocha, J. Loscertales, J. Catalano, L. Larratt, V. Rossiev, I. Bence‐Bruckler, C. Geisler, M. Montillo, K. Fischer, A. Fink, M. Hallek, J. Bloehdorn, R. Busch, A. Benner, H. Döhner, N. Valente, M. Wenger, S. Stilgenbauer, D. Dornan (2014)
PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia.Blood, 124 3
-
K. Fischer, P. Cramer, R. Busch, S. Böttcher, J. Bahlo, J. Schubert, K. Pflüger, S. Schott, V. Goede, S. Isfort, J. Tresckow, A. Fink, A. Bühler, D. Winkler, K. Kreuzer, P. Staib, M. Ritgen, M. Kneba, H. Döhner, B. Eichhorst, M. Hallek, S. Stilgenbauer, C. Wendtner (2012)
Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 26
-
R. Furman, J. Sharman, S. Coutre, B. Cheson, J. Pagel, P. Hillmen, J. Barrientos, A. Zelenetz, T. Kipps, I. Flinn, P. Ghia, H. Eradat, T. Ervin, N. Lamanna, B. Coiffier, A. Pettitt, Shuo Ma, S. Stilgenbauer, P. Cramer, Maria Aiello, D. Johnson, L. Miller, Daniel Li, T. Jahn, R. Dansey, M. Hallek, S. O'brien (2014)
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.The New England journal of medicine, 370 11
-
R. Damle, T. Wasil, F. Fais, F. Ghiotto, A. Valetto, S. Allen, A. Buchbinder, D. Budman, K. Dittmar, J. Kolitz, S. Lichtman, P. Schulman, V. Vinciguerra, K. Rai, M. Ferrarini, N. Chiorazzi (1999)
Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.Blood, 94 6
- Publisher
- Springer Journals
- Copyright
- Copyright © 2016 by Springer Science+Business Media New York
- Subject
- Medicine & Public Health; Hematology; Oncology; Geriatrics/Gerontology
- ISSN
- 1558-8211
- eISSN
- 1558-822X
- DOI
- 10.1007/s11899-015-0294-x
- pmid
- 26748932
- Publisher site
- See Article on Publisher Site
Abstract
As novel strategies for treatment and prognostication of chronic lymphocytic leukemia (CLL) evolve, the traditional Rai and Binet systems can now be updated with more modern prognostic markers. This is a review of the latest articles which combine studies from major CLL centers to summarize major prognostic factors for patients diagnosed with CLL. The prognostic information can be categorized into three categories: genetic abnormalities which include 17p, 11q, and immunoglobulin heavy chain variable (IGHV) abnormalities; biochemical abnormalities and cell surface markers which include serum thymidine kinase, β-2-microglobulin, CD49d, CD38, and ZAP-70 levels; and patient characteristics which include sex, age, and performance status.
Journal
Current Hematologic Malignancy Reports – Springer Journals
Published: Jan 9, 2016